
Claims

1. A compound for the suppression or reduction of a motor complication,

the compound being represented by the formula (IC):



(IC)

or a pharmaceutically acceptable salt thereof,


wherein the motor complication is a side effect of L-DOPA and/or dopamine agonist therapy.

2. The compound according to claim 1, wherein the motor complication is wearing-off phenomenon.

3. The compound according to claim 1, wherein the motor complication is on-off fluctuation.

4. A pharmaceutical composition for the suppression or reduction of a motor complication,

the composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula (IC):



(IC)


or a pharmaceutically acceptable salt thereof,

wherein the motor complication is a side effect of L-DOPA and/or dopamine agonist therapy.

5. The composition according to claim 4, wherein the motor complication is wearing-off phenomenon.

6. The composition according to claim 4, wherein the motor complication is on-off fluctuation.

7. A pharmaceutical composition comprising (a) a compound represented by the formula (IC):



(IC) ,


or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist.

8. The pharmaceutical composition according to claim 7 further

comprising a pharmaceutically acceptable excipient.

9. The pharmaceutical composition according to claim 7 or 8, wherein the dopamine agonist is pramipexole, talipexole, ropinirole, cabergoline, or pergolide, or a pharmaceutically acceptable salt thereof.

10. A combination of compounds for the treatment and/or prophylaxis of Parkinson's disease, comprising (a) a compound represented by the formula (IC):



(IC)


or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist.

11. The combination according to claim 10, wherein (a) and (b) are intended for administration simultaneously or separately at an interval.

12. The combination according to claim 10 or 11, wherein the Parkinson's disease is in advanced stage.

13. The pharmaceutical composition according to any one of claims 10 to 12, wherein the dopamine agonist is pramipexole, talipexole, ropinirole, cabergoline, or pergolide, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition for the treatment and/or prophylaxis of Parkinson's disease, comprising (a) a compound represented by the formula (IC):



(IC)

or a pharmaceutically acceptable salt thereof, and (b) L-DOPR and/or a dopamine agonist, and (c) a pharmaceutically acceptable excipient.


15. The composition according to claim 14, wherein (a), (b) and (c) are provided as a single unit dose.

16. The composition according to claim 14, wherein (a), (b) and (c) are provided in separate unit doses for administration simultaneously or separately at an interval.

17. The composition according to any one of claims 14 to 16, wherein the Parkinson's disease is in advanced stage.

18. The pharmaceutical composition according to any one of claims 14 to 17, wherein the dopamine agonist is pramipexole, talipexole, ropinirole, cabergoline, or pergolide, or a pharmaceutically acceptable salt thereof.

19. Use of a combination of (a) a compound represented by the formula (IC):



(IC)


or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist, in the manufacture of a medicament for the treatment and/or prophylaxis of Parkinson's disease.

20. The use according to claim 19, wherein (a) and (b) are intended for administration simultaneously or separately at an interval.

21. The use according to any one of claims 19 to 20, wherein the Parkinson's disease is in advanced stage.

22. The use according to any one of claims 19 to 21, wherein the dopamine agonist is pramipexole, talipexole, ropinirole, cabergoline, or pergolide, or a pharmaceutically acceptable salt thereof.

23. A kit comprising (a) a first component comprising a compound represented by the formula (IC):



(IC)

or a pharmaceutically acceptable salt thereof, (b) a second component comprising L-DOPA and/or a dopamine agonist, and (c) instructions for using the first and second components.